Adverse Event reporting information can be found in footer

Request a Meeting



Research question: This study aimed to establish the efficacy and safety of ovarian stimulation with a follitropin delta individualised fixed-dose regimen based on serum anti-Müllerian hormone (AMH) concentration and body weight versus conventional follitropin beta dosing in Japanese women.

Design: This randomised, controlled, assessor-blind, multicentre, non-inferiority trial was conducted in 347 Japanese in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) patients. They were randomised to individualised follitropin delta (AMH <15 pmol/l: 12 μg/day; AMH ≥15 pmol/l: 0.10–0.19 μg/kg/day; minimum 6 μg/day; maximum 12 μg/day) or conventional follitropin beta (150 IU/day for the first 5 days, with potential subsequent dose adjustments).

Primary endpoint: The primary endpoint was the number of oocytes retrieved with a pre-specified non-inferiority margin (−3.0 oocytes).

Secondary endpoints:

  • Efficacy secondary endpoints included duration of stimulation, total gonadotrophin dose, distribution of number of oocytes retrieved, extreme ovarian response in at-risk populations (defined as <4 oocytes retrieved for women with AMH <15 pmol/l and ≥15 or ≥20 oocytes retrieved for women with AMH ≥15 pmol/l), pregnancy outcomes, including clinical pregnancy and live birth rates.
  • Safety evaluations included adverse events, early and late ovarian hyperstimulation syndrome (OHSS), preventive interventions for early OHSS, cycle cancellation or blastocyst transfer cancellation due to excessive ovarian response/OHSS risk, and local tolerability.

Results: The primary trial objective was met, as non-inferiority was established for number of oocytes retrieved for individualised follitropin delta dosing compared with conventional follitropin beta dosing (9.3 versus 10.5; lower boundary of 95% CI−2.3). The occurrence of OHSS was reduced to approximately half with individualised compared with conventional dosing, with an incidence of 11.2% versus 19.8% (p=0.021) for OHSS of any grade and 7.1% versus 14.1% (p=0.027) for moderate/severe OHSS. The live-birth rate per started cycle was 23.5% for individualised dosing and 18.6% for conventional dosing.

Conclusions: Dosing with individualised follitropin delta in Japanese women is non-inferior to conventional dosing with follitropin beta for number of oocytes retrieved. The individualised approach shows a favourable benefit–risk profile, providing a statistically significant and clinically relevant reduction in the incidence of OHSS, without compromising live-birth rates.



  1. Ishihara O and Arce JC. Reproductive biomedicine online 2021;42:909–918.

Job Code: UK-REK-2300016 - Date of preparation: July 2023


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.